Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03505346
Other study ID # EUDRA-CT: 2017-002712-14
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date January 1, 2024
Est. completion date December 1, 2025

Study information

Verified date November 2023
Source Rigshospitalet, Denmark
Contact Simon Bentsen, MD
Phone +4535451793
Email simon.bentsen.01@regionh.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim is to examine the expression of αvβ3 integrin using a novel selective radiotracer in patients with chronich ischemic heart disease and investigate if it is a suitable tool for predicting myocardial recovery and thus prognosis after intervention.


Description:

Ischemic heart disease is worldwide the single most frequent cause of death. The number of patients surviving acute myocardial injury is increasing due to improved acute treatment. However, after the initial repair, the tissue undergoes a remodeling phase to compensate for the damaged area. This re-modeling phase can change the structure end geometry of the heart resulting in lower ejection fraction, leading to cardiac dysfunction, which eventually leads to heart failure. Ischemic heart disease is most commently caused by arteriosclerosis of the coronary artery. If chronic ischemic heart disease is left untreated, it will lead to symptoms to the patient. These symptons occur when the myocardiel oxygen demand exceeds the oxygen provided, due to coronary occlusion. If the heart suffers from ischemia, the tissue reacts strongly to the hypoxia. The body will as a compensatory mechanism create new vessel to provide the tissue with oxygen. This is known as the biological process of angiogenesis. This complex process involves different angiogenic and pro-fibrotic transcription factors that initiate the restoration of capillaries by sprouting from the existing endothelial cells in response to hypoxia. Integrin αvβ3 is a transmembrane cell surface receptor that is markedly upregulated in states of angiogenesis. It facilitates migration and proliferation and thereby allowing cells to respond to extracellular environment. Integrin αvβ3 is thus a key player in the angiogenic process. The integrin αvβ3 has a binding site for an RGD peptide (Arg-Gly-Asp motif) and this can be targeted by PET tracers. RGD-based PET tracers have been shown to accumulate at the site of myocardial necrosis in both human and animal studies. The uptake before interventions may correlate to recovery of cardiac function and thus serve as a prognostic marker after intervention.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 42
Est. completion date December 1, 2025
Est. primary completion date December 1, 2025
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria: - Age over 50 years - Patient with known chornic ischemic Heart disease admitted to Rigshospitalet to either PCI og CABG Exclusion Criteria: - No prior history of Heart surgery - Not treated with anti-angiogenic medicine - Subject with pacemaker, cochlear implant or insulin pump - Pregnancy - Lactation - Severe claustrophobia - Severe obesity (weight above 140kg) - Conversion from PCI to CABG - If a subject is in the fertile age, a pregnancy test will be use prior to injection to the PET_tracer - If a subject is having a severe allergic reaction to the PET-tracer, the person will be excluded for the rest of the trial - If the PET-tracer is administered subcutaneous, the person will be excluded for the rest of the trial¨ - Type I or II diabetes

Study Design


Intervention

Drug:
68Ga-NODAGA-E[c(RGDyK)]2
200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV.

Locations

Country Name City State
Denmark Department of Physiology, Nuclear Medicine and PET Copenhagen Region Hovedstaden

Sponsors (1)

Lead Sponsor Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate myocardial angiogenesis Analysing change in uptake of 68Ga-NODAGA-E[c(RGDyK)]2 Positron Emission Tomography after intervention 30-35 days
Secondary Correlation between 68Ga-NODAGA-E[c(RGDyK)]2 and myocardial perfusion Correlation between uptake of 68Ga-NODAGA-E[c(RGDyK)]2 and change in myocardial perfusion after intervention using Rubidium 82 Positron Emission Tomography 30-35 days
Secondary Correlation between 68Ga-NODAGA-E[c(RGDyK)]2 and functional recovery Correlation between uptake of 68Ga-NODAGA-E[c(RGDyK)]2 and functional recovery using Magnetic Resonance after intervention 30-35 days
Secondary Correlatino between 68Ga-NODAGA-E[c(RGDyK)]2 and viability Correlation between uptake of 68Ga-NODAGA-E[c(RGDyK)]2 and viability using Flour-Deoxy-Glucose Positron Emission Tomography after intervention 30-35 days
See also
  Status Clinical Trial Phase
Recruiting NCT03809689 - Study of Cardiac Lesions Angiogenesis by 68Ga-NODAGA-RGD Cardiac PET N/A
Recruiting NCT02439541 - Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Ischemic Cardiomyopathy Phase 1/Phase 2
Completed NCT04916912 - Results of Coronary Artery Bypass Grafting in Obese Patients
Completed NCT00824005 - Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study) Phase 2
Completed NCT03796741 - STable Coronary Artery Diseases RegisTry
Completed NCT03043742 - Stem Cell Heart Injections During Laser Revascularization Surgery for Treatment of Chronic Ischemic Heart Disease Phase 1
Terminated NCT01666132 - METHOD - Bone Marrow Derived Mononuclear Cells in Chronic Ischemic Disease Phase 1/Phase 2
Completed NCT01727063 - Cell Therapy in Severe Chronic Ischemic Heart Disease Phase 3
Completed NCT01449032 - MesenchYmal STROMAL CELL Therapy in Patients With Chronic Myocardial Ischemia (MyStromalCell Trial) Phase 2